Literature DB >> 15801944

Raloxifene pharmacokinetics in males with normal and impaired renal function.

David Czock1, Frieder Keller, Mette Heringa, Franz Maximilian Rasche.   

Abstract

AIMS: To compare raloxifene pharmacokinetics between renally impaired and healthy subjects.
METHODS: Raloxifene 120 mg was administered to 10 males with renal impairment (creatinine 2-4 mg dl(-1)) and to 10 healthy males. Data were analysed by two noncompartmental and one compartmental nonlinear regression methods.
RESULTS: The medians (95% confidence interval) of the area under the curves (AUC) were 35.1 (25.8, 74) and 20.5 (16.8, 28.0) h ng ml(-1) per mg kg(-1), P < 0.01, and of the clearances (CL/F) were 28.5 (13.5, 38.8) and 48.8 (35.8, 59.4) l h(-1) kg(-1), P < 0.01, in renally impaired and healthy subjects, respectively. 95% Confidence intervals on the differences for AUC and CL/F were 6.5-44.1 and -35.1 to -7.9, respectively.
CONCLUSION: Exposure to raloxifene was twice as high in males with renal impairment compared with healthy subjects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15801944      PMCID: PMC1884804          DOI: 10.1111/j.1365-2125.2004.02326.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  Enterohepatic circulation model for population pharmacokinetic analysis.

Authors:  T Funaki
Journal:  J Pharm Pharmacol       Date:  1999-10       Impact factor: 3.765

2.  Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity.

Authors:  J A Dodge; C W Lugar; S Cho; L L Short; M Sato; N N Yang; L A Spangle; M J Martin; D L Phillips; A L Glasebrook; J J Osborne; C A Frolik; H U Bryant
Journal:  J Steroid Biochem Mol Biol       Date:  1997-04       Impact factor: 4.292

3.  Pharmacokinetics of estulic [corrected] in humans.

Authors:  Y Cherruault; V B Sarin
Journal:  Int J Biomed Comput       Date:  1986-03

4.  Calculating confidence intervals for some non-parametric analyses.

Authors:  M J Campbell; M J Gardner
Journal:  Br Med J (Clin Res Ed)       Date:  1988-05-21

Review 5.  Pharmacokinetics of raloxifene and its clinical application.

Authors:  D Hochner-Celnikier
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1999-07       Impact factor: 2.435

Review 6.  Pharmacokinetics of selective estrogen receptor modulators.

Authors:  Karla C Morello; Gregory T Wurz; Michael W DeGregorio
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis.

Authors:  Eddy Hernández; Raquel Valera; Evelyn Alonzo; Mariela Bajares-Lilue; Raúl Carlini; Freya Capriles; Ruby Martinis; Ezequiel Bellorin-Font; José R Weisinger
Journal:  Kidney Int       Date:  2003-06       Impact factor: 10.612

8.  Disposition and metabolism of a new benzothiophene antiestrogen in rats, dogs and monkeys.

Authors:  T D Lindstrom; N G Whitaker; G W Whitaker
Journal:  Xenobiotica       Date:  1984-11       Impact factor: 1.908

  8 in total
  7 in total

1.  Effects of UGT1A1*28 polymorphism on raloxifene pharmacokinetics and pharmacodynamics.

Authors:  Jurij Trontelj; Janja Marc; Andrej Zavratnik; Marija Bogataj; Ales Mrhar
Journal:  Br J Clin Pharmacol       Date:  2009-04       Impact factor: 4.335

Review 2.  Raloxifene: a review of its use in the prevention of invasive breast cancer.

Authors:  Marit D Moen; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

3.  Quantitative prediction and clinical evaluation of an unexplored herb-drug interaction mechanism in healthy volunteers.

Authors:  B T Gufford; J T Barr; V González-Pérez; M E Layton; J R White; N H Oberlies; M F Paine
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-11-28

4.  Raloxifene in hemodialysis patients.

Authors:  Frieder Keller
Journal:  Int J Endocrinol Metab       Date:  2012-06-30

5.  Pros and cons of the tuberculosis drugome approach--an empirical analysis.

Authors:  Feng-Chi Chen; Yu-Chieh Liao; Jie-Mao Huang; Chieh-Hua Lin; Yih-Yuan Chen; Horng-Yunn Dou; Chao Agnes Hsiung
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240

6.  A systematic and prospectively validated approach for identifying synergistic drug combinations against malaria.

Authors:  Yasaman KalantarMotamedi; Richard T Eastman; Rajarshi Guha; Andreas Bender
Journal:  Malar J       Date:  2018-04-11       Impact factor: 2.979

7.  Selective estrogen receptor modulators decrease invasiveness in pituitary adenoma cell lines AtT-20 and TtT/GF by affecting expression of MMP-14 and ADAM12.

Authors:  Zhuo Zhang; Jörg W Bartsch; Julia Benzel; Ting Lei; Christopher Nimsky; Benjamin Voellger
Journal:  FEBS Open Bio       Date:  2020-10-26       Impact factor: 2.792

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.